Skip to main content

RMD

Stock
Health Care
Medical Instruments & Supplies

Performance overview

RMD Price
Price Chart

Forward-looking statistics

Beta
0.62
Risk
33.13%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

at resmed (nyse: rmd, asx: rmd) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. our cloud-connected medical devices transform care for people with sleep apnea, copd and other chronic diseases. our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. by enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 120 countries.

Company info

SectorHealth Care
IndustryMedical Instruments & Supplies
Employees8K
Market cap$31.0B

Fundamentals

Enterprise value$37.7B
Revenue$5.0B
Revenue per employee—
Profit margin26.15%
Debt to equity15.14

Security info

ExchangeNyse American
Type of shareCommon Stock
Earnings per share (EPS)$8.92
Dividend per share$2.12
Revenue per share$34.20
Avg trading volume (30 day)$214M
Avg trading volume (10 day)$250M
Put-call ratio—

Macro factor sensitivity

Growth-0.9
Credit+3.1
Liquidity+0.6
Inflation-4.4
Commodities-0.0
Interest Rates-0.7

Valuation

Dividend yield0.82%
PEG Ratio24.97
Price to sales7.50
P/E Ratio24.97
Enterprise Value to Revenue7.51
Price to book6.79

Upcoming events

Next earnings dayApril 24, 2025
Next dividend day—
Ex. dividend dayMay 8, 2025

News

Buy These 5 Low-Leverage Stocks Amid Impressive Retail Sales Data

With retail sales rebounding and Wall Street gaining, low-leverage stocks like NVS, RMD, WAB, ESLT and INGR offer scope for upside.

Zacks Investment Research (July 18, 2025)
Can CorMedix (CRMD) Keep the Earnings Surprise Streak Alive?

CorMedix (CRMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Investment Research (July 14, 2025)
Is TORM (TRMD) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research (July 8, 2025)
All You Need to Know About ResMed (RMD) Rating Upgrade to Buy

ResMed (RMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research (June 25, 2025)
ResMed Boasts Double-Digit EPS Growth, Tariff Exemption: Analysts Boost Price Forecast

On Wednesday, ResMed Inc RMD reported that third-quarter adjusted EPS was $2.37, beating the consensus of $2.36.

Benzinga (April 24, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free